Tuesday Talk with Ilze Bot in Leiden
Meetings
Breaking the Cycle of Hearth Attacks
Why do heart attacks and strokes remain a threat – even in patients receiving treatment? These life-threatening events are often caused by unstable plaques in the bood vessels, which can suddenly rapture. while cholesterol-lowering medication reduces the risk, it’s not always enough. A growing body of scientific evidence suggests that the immune system may hold the key to understanding – and preventing – these dangerous complications.
At the Tuesday Talk, Professor Ilze Bot has explored how certain immune cells play a role in atherosclerosis, and what new treatment strategies might help to reduce the risk of sudden cardiovascular events.

Second Annual Meeting in Sweden
ULEI hosted our 2nd Annual Meeting at the Grand Hotel Lund, Sweden, between the 9th and 10th of October 2025.
The meeting was a valuable opportunity for in-person discussions, sharing results, and planning future activities. An important part of the event was the roundtable discussion to assess results, upcoming tasks, risks, and mitigation strategies in R&D work packages.
Additionally, the ULEI team updated on the activities in the Cardiogenomics Portfolio, including the upcoming EIC Portfolio event on March 16-17, 2026, focused on networking and a Tech-to-Market event in Leiden organized by ULEI, and INN-ACTA shared information about the outreach to patient organisations. Importantly, the coordinator presented the management and coordination activities and provided details for the upcoming reporting period and review meeting.
The meeting strengthened our connections and commitment within the consortium to further knowledge and identify new biomarkers and therapeutic targets for atherosclerosis.
Thank you to all partners for dedication and contributions, and a special thanks to the organizer for facilitating the meeting and welcoming us to Lund.
The ULUND Team at the Atheroma Club
Meetings
Samuel Andersson and Anthi Chalou from ULUND team presented posters based on their work in B-specific in the Annual Atheroma Club Meeting, Ystad, Sweden held during 22-24th October 2025. Atheroma Club is an annual meeting between junior and senior cardiovascular researchers from Lund University, Karolinska Institute, and Gothenburg University that has been taking place for over three decades now.

KUL team participated at the Symposium on Autoantibodies
Meetings

Jill wins Best Presentation Award at the DuSRA Annual Meeting
Meetings
During the two-day annual meeting of the Dutch Society for Aging Research (DuSRA) in Amsterdam, Jill was honored with the Best Presentation Award. She presented her recent work on mTOR inhibition in aging and atherosclerosis, showing how rapamycin may reduce (B cell) inflammation and promote healthier aging.

B cell research presented at the Gordon Research Conference on Atherosclerosis
Meetings
In June 2025, Bram, Amanda and Jill attended the Gordon Research Conference on Atherosclerosis in Castelldefels, Spain. During this international meeting, leading scientists and clinicians shared and discussed the latest developments in atherosclerosis research. Bram, Amanda, and Jill all presented posters showcasing their work, with Jill and Amanda highlighting our research on age-associated B cells (ABCs) in atherosclerosis. The conference provided an excellent opportunity to connect with fellow researchers and discuss cutting-edge approaches in the field.

Award for Anna Witteveen at the DCVA-NLHI
Meetings

Official opening of the MabMine antibody discovery platform at KUL
Meetings
On the 27th of May was the official opening of the novel MabMine antibody discovery platform at Campus Gasthuisberg in Leuven with the participation of about 60 invited academic and industrial collaborators.
The new facility is dedicated to advancing the MabMine antibody discovery platform and is equipped with state-of-the-art technology for:
-
Single B cell screening and isolation;
-
B cell receptor (BCR) sequencing;
-
Recombinant antibody production
-
Antibody characterization.
New Lab Supported by Vlaamse Veerkracht/ NextGenerationEU Grant — PharmAbs
B-specific projects were also highlighted at the event!


Amanda Foks will participate in the Dutch CardioVascular Alliance Leadership Program
Meetings
B-specific coordinator Amanda Foks, has been selected to join the Dutch CardioVascular Alliance (DCVA) Leadership Program 2025-2026. As part of the program, Amanda will work together with fellow scientists, clinicians and DCVA partners on current challenges in cardiovascular research, care and policy. Amanda is very excited to join this program and to contribute to the mission of the DCVA.
More information about the DCVA can be found via this link: https://dcvalliance.nl/











